FDA 就 CMO 资质确认问题向 AACE Pharmaceuticals 发出警告信
FDA Warning Letter with Supplier Qualification Observations
FDA 公布向美国制药公司 AACE Pharmaceuticals 发出的警告信,指其在 CMO 资质确认程序上存在不足。该检查因该公司的合同制造商存在多项 CGMP 违规、并导致进口警示和药品召回而安排,AACE 在发现该 CMO 多项 CGMP 缺陷后仍将其列为合格,三年后又在未评估后续 CAPA 是否充分解决已识别缺陷的情况下重新确认其资格。
以 FDA 警告信为例,呈现 CMO 资质确认中偏差评估、资格取消以及 COA 比对不足以替代质量责任的审查要点。
CMO and Supplier Qualification in outsourcing activities are always hot topics in inspections. The U.S. Food and Drug Administration (FDA) recently posted a Warning Letter sent to the pharmaceutical company AACE Pharmaceuticals in the US, criticizing their CMO qualification procedures. The inspection was scheduled because of problems at the company's contract manufacturer (CMO), where "multiple CGMP violations" were revealed, resulting in an Import Alert and drug product recalls. The CMO manufactures ophthalmic products for AACE. Although AACE identified several CGMP deficiencies at this CMO, the CMO was qualified as approved. Furthermore, it was even re-qualified three years later, "without evaluating whether subsequent corrective actions and preventive actions adequately addressed the identified deficiencies". So AACE released products for distribution "without adequate procedures to ensure that the ophthalmic drug products (…) met appropriate quality attributes". As a consequence, AACE has revised its procedures to ensure that GMP deviations at a CMO and the associated CAPA plans are assessed accordingly. This was not sufficient for FDA. The agency requires details on how to assess the deviations, how to disqualify CMOs and how to evaluate qualification status of other CMOs. Before releasing a product, AACE was comparing certificate of analysis (COA) data against the pre-approved specification. FDA clearly states, that this does not overcome the "responsibility to evaluate, qualify, audit, and monitor" CMOs. A firm "should have a robust qualification process" of CMOs, based on quality risk management principles.
来源:ECA GMP News · gmp-compliance.org